undamentalytics Newsletter
Sign in

Whitehawk Therapeutics, Inc. (WHWK) stock

Add to watchlist

Add holding +

NASDAQ: WHWK Nasdaq Biotechnology Next results ~November 5, 2026

E Fundamentals grade

Whitehawk Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

Not valued: the figures our models need are missing or failed our data-quality checks.

Price vs value

No model value: cash-flow, stock-pay or share-count figures missing or out of date. How we value companies.

Whitehawk Therapeutics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 3 selling0 purchases and 14 sales by directors and officers, last 12 monthsInsider trades
  • Funds58 adding, 22 cuttingOf 19 active managers that changed their stake, 12 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Whitehawk Therapeutics files

Where Whitehawk Therapeutics stands after its latest 10-Q

Whitehawk Therapeutics has little or no product revenue yet; it used $69m of cash in the twelve months to June 2026. That puts it 118 of 122 for growth among the biotechnology companies we cover. The diluted share count is up 78.2% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades E. It passes 2 of our 2 financial-health checks.

Our models give no value for Whitehawk Therapeutics at present, so past values are not shown.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Whitehawk Therapeutics, Inc.'s trailing-twelve-month revenue fell 100.0% year on year, with a free-cash-flow margin of -1371.4%. Where it lags: revenue growth of -100.0% ranks 167 of 172 biotechnology companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 28.1% while net income fell 666.3%: a 694pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Whitehawk Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 100.0% over the last 12 months.
  • Loss-making. Operating margin is -1601.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 1341.5 points on a year ago.
  • Burning cash. Free cash flow was -1371.4% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 138.2% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.20 against an average estimate of -$0.26: beat by 23.1%
Share reaction
+17.0% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 5, 2026; average EPS estimate -$0.24

Whitehawk Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.7%
  • 1 week-0.6%
  • 1 month-15.7%
  • This year+28.9%
  • 1 year+30.0%
  • 5 years-89.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$0
Operating margin
-1601.1%
Net margin
-288.3%
EPS (TTM, diluted)
$-1.10

Growth

Revenue growth
−100.0%
Change in growth rate
+0.0 pts
Share count change
+78.2%

Cash

Free cash flow (TTM)
-$69.3M
FCF margin
-1371.4%
Stock pay % of revenue
138.2%

Earnings

Last results
August 6, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Whitehawk Therapeutics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: cash-flow, stock-pay or share-count figures missing or out of date.

Valuation models

We value Whitehawk Therapeutics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.07 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no positive revenue in the latest twelve months
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Whitehawk Therapeutics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20182019202020212022202320242025Now
Share price$25.50$9.36$14.70$24.15$12.83$2.02$3.15$2.42$3.12
Market value$58m$25m$37m$215m$289m$54m$85m$150m$227m
+ Net debt (− = net cash)−$63m−$39m$6m−$149m−$39m−$63m−$29m−$38m−$85m
Enterprise value−$5m−$13m$43m$67m$250m−$9m$57m$112m$141m
Multiples
Price / sales 2.9x—2.7x15.4x19.0x2.2x3.3x21.0x—
Price / earnings —————————
Price / free cash flow —————————
EV / EBITDA —————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Whitehawk Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -39.7% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -411.9%; its worst year was -1601.1%.

  • Discipline 0 / 20

    The diluted share count rose 2579.2% over five years; stock-based pay has been a median 49.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.24 (range −$0.27 to −$0.21) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.97 +44% — −100%
Next −$0.99 −2% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −15.9% on 90 days ago. In the last 30 days, 2 analysts raised Whitehawk Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Whitehawk Therapeutics, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.15 Current fiscal year, 60 days ago: −$1.11 Current fiscal year, 30 days ago: −$0.96 Current fiscal year, 7 days ago: −$0.96 Current fiscal year, Now: −$0.97 −$0.97 Next fiscal year, 90 days ago: −$1.17 Next fiscal year, 60 days ago: −$1.10 Next fiscal year, 30 days ago: −$0.99 Next fiscal year, 7 days ago: −$0.99 Next fiscal year, Now: −$0.99 −$0.99

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.15−$1.17
60 days ago −$1.11−$1.10
30 days ago −$0.96−$0.99
7 days ago −$0.96−$0.99
Now −$0.97−$0.99

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.26 −$0.20 +23.1%
Mar 2026 −$0.33 −$0.32 +2.0%
Dec 2025 −$0.27 −$0.34 −25.9%
Sept 2025 −$0.22 −$0.25 −15.4%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

9 analysts, Oct 2026
Buy667%
Hold333%
Sell00%

Monthly trend

  1. Oct 20261539
  2. Sep 20261438
  3. Aug 20261438

Counts of recommendations published by analysts covering Whitehawk Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.4%
of tradable shares
Days to cover
7.25
at average volume
Short interest, 1 month
−4%
to October 15, 2026
Held by institutions
81%
of shares
Held by insiders
12.6%
of shares
Employees
32
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
WHWK+64%−47%−84%+56%−23%+29%
Industry peers (median)−36%−57%−17%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
WHWK50%42%33%58%50%46%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
WHWK−54%−54%−85%−46%−61%−43%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since February 16, 2018: 98% from March 19, 2018 to July 2, 2024. Getting back needed a 5582% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.99 – $5.10
From 52-week high
−38.8%
vs 50-day average
−18.5%
vs 200-day average
−18.7%
Volatility (1 year)
69%
Beta vs S&P 500
1.60

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±6.2%
After a week
5 up, 7 down
typical move ±9.5%
After a month
7 up, 5 down
typical move ±13.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 +17.0% +0.5% +15.0% +13.0%
May 7, 2026 −4.3% +0.5% +22.9% −3.1%
March 12, 2026 −2.5% −2.1% −10.5% −13.5%
November 6, 2025 −8.0% −1.0% −7.1% +6.2%
August 7, 2025 −2.8% +0.7% −10.0% −0.6%
May 8, 2025 +4.3% +0.6% +3.7% +20.2%
March 18, 2025 −3.8% 0.0% −7.1% −26.7%
November 6, 2024 +5.5% +3.3% +9.0% +21.6%
August 7, 2024 −3.6% +1.6% −0.7% +30.7%
May 8, 2024 −10.9% +0.6% −12.8% −17.5%
March 13, 2024 +5.7% −0.4% +12.9% +1.0%
November 8, 2023 −6.6% −0.7% −2.3% +2.9%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Whitehawk Therapeutics, Inc. in five measures

Fundamentals grade E
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Whitehawk Therapeutics, Inc.
$0 $10M $20M $30M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $23.3M Revenue (TTM), FY23 Q4: $24.4M Revenue (TTM), FY24 Q1: $23.8M Revenue (TTM), FY24 Q2: $23.8M Revenue (TTM), FY24 Q3: $25.1M Revenue (TTM), FY24 Q4: $26M Revenue (TTM), FY25 Q1: $27.8M Revenue (TTM), FY25 Q2: $21.6M Revenue (TTM), FY25 Q3: $14.4M Revenue (TTM), FY25 Q4: $7.1M Revenue (TTM), FY26 Q1: $0 Revenue (TTM), FY26 Q2: $0 $0

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $23.3M
FY23 Q4 $24.4M
FY24 Q1 $23.8M
FY24 Q2 $23.8M
FY24 Q3 $25.1M
FY24 Q4 $26M
FY25 Q1 $27.8M
FY25 Q2 $21.6M
FY25 Q3 $14.4M
FY25 Q4 $7.1M
FY26 Q1 $0
FY26 Q2 $0
Revenue growth, TTM YoY Whitehawk Therapeutics, Inc.
-100% -50% 0% 50% 100% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -2.6% Revenue growth, TTM YoY, FY23 Q4: 60.1% Revenue growth, TTM YoY, FY24 Q1: 27.0% Revenue growth, TTM YoY, FY24 Q2: 10.6% Revenue growth, TTM YoY, FY24 Q3: 7.8% Revenue growth, TTM YoY, FY24 Q4: 6.7% Revenue growth, TTM YoY, FY25 Q1: 16.5% Revenue growth, TTM YoY, FY25 Q2: -9.3% Revenue growth, TTM YoY, FY25 Q3: -42.6% Revenue growth, TTM YoY, FY25 Q4: -72.5% Revenue growth, TTM YoY, FY26 Q1: -100.0% Revenue growth, TTM YoY, FY26 Q2: -100.0% -100.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -2.6%
FY23 Q4 60.1%
FY24 Q1 27.0%
FY24 Q2 10.6%
FY24 Q3 7.8%
FY24 Q4 6.7%
FY25 Q1 16.5%
FY25 Q2 -9.3%
FY25 Q3 -42.6%
FY25 Q4 -72.5%
FY26 Q1 -100.0%
FY26 Q2 -100.0%
Operating margin (TTM) Whitehawk Therapeutics, Inc.
-2000% -1500% -1000% -500% 0% FY23 Q1 FY23 Q4 FY24 Q3 FY25 Q4 Operating margin (TTM), FY23 Q1: -349.9% Operating margin (TTM), FY23 Q2: -310.5% Operating margin (TTM), FY23 Q3: -299.7% Operating margin (TTM), FY23 Q4: -295.4% Operating margin (TTM), FY24 Q1: -313.0% Operating margin (TTM), FY24 Q2: -296.7% Operating margin (TTM), FY24 Q3: -264.2% Operating margin (TTM), FY24 Q4: -259.6% Operating margin (TTM), FY25 Q1: -227.4% Operating margin (TTM), FY25 Q2: -473.8% Operating margin (TTM), FY25 Q3: -754.0% Operating margin (TTM), FY25 Q4: -1601.1% -1601.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q1 -349.9%
FY23 Q2 -310.5%
FY23 Q3 -299.7%
FY23 Q4 -295.4%
FY24 Q1 -313.0%
FY24 Q2 -296.7%
FY24 Q3 -264.2%
FY24 Q4 -259.6%
FY25 Q1 -227.4%
FY25 Q2 -473.8%
FY25 Q3 -754.0%
FY25 Q4 -1601.1%
FCF margin (TTM) Whitehawk Therapeutics, Inc.
-1500% -1000% -500% 0% FY23 Q1 FY23 Q4 FY24 Q3 FY25 Q4 FCF margin (TTM), FY23 Q1: -284.0% FCF margin (TTM), FY23 Q2: -277.7% FCF margin (TTM), FY23 Q3: -277.6% FCF margin (TTM), FY23 Q4: -261.3% FCF margin (TTM), FY24 Q1: -257.3% FCF margin (TTM), FY24 Q2: -225.0% FCF margin (TTM), FY24 Q3: -225.1% FCF margin (TTM), FY24 Q4: -235.6% FCF margin (TTM), FY25 Q1: -191.6% FCF margin (TTM), FY25 Q2: -446.8% FCF margin (TTM), FY25 Q3: -667.3% FCF margin (TTM), FY25 Q4: -1371.4% -1371.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q1 -284.0%
FY23 Q2 -277.7%
FY23 Q3 -277.6%
FY23 Q4 -261.3%
FY24 Q1 -257.3%
FY24 Q2 -225.0%
FY24 Q3 -225.1%
FY24 Q4 -235.6%
FY25 Q1 -191.6%
FY25 Q2 -446.8%
FY25 Q3 -667.3%
FY25 Q4 -1371.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 20 0 14 14 15 24 26 7 0
Gross profit — — — 14 14 22 23 6 0
EBITDA −11 −24 −3 −111 −63 −72 −67 −114 −86
Operating income −11 −24 −3 −111 −63 −72 −67 −114 −86
Net income −10 −23 −3 −110 −61 −66 −64 −21 −80
Diluted EPS −$0.31 −$8.55 −$1.76 −$12.41 −$2.69 −$2.44 −$2.36 −$0.33 −$1.10
Growth (year on year)
Revenue — −100.0% — 0.0% +8.7% +60.1% +6.7% −72.5% −100.0%
Margins
Gross margin — — — 100.0% 91.2% 88.5% 88.4% 89.4% —
EBITDA margin −55.2% — −18.1% −793.7% −410.9% −294.7% −258.9% <−999% —
Operating margin −55.5% — −18.2% −794.4% −411.9% −295.4% −259.6% <−999% —
Net margin −51.6% — −24.8% −786.4% −397.7% −270.0% −245.1% −288.3% —
Free-cash-flow margin −29.0% — −90.9% −160.5% −329.2% −261.3% −235.6% <−999% —
Cash flow
Cash from operations −6 −24 −13 −22 −50 −60 −60 −97 −69
Capital spending 0 0 0 0 0 4 2 1 0
Free cash flow −6 −24 −13 −22 −50 −64 −61 −98 −69
Stock-based pay 3 1 0 2 10 12 11 10 9
Free cash flow after stock pay −9 −25 −13 −25 −60 −76 −72 −108 −78
Balance sheet
Cash 63 39 4 149 39 63 29 38 85
Total debt 0 0 10 — 0 0 0 0 0
Net debt (negative = net cash) −63 −39 6 −149 −39 −63 −29 −38 −85
Diluted shares 2m 3m 3m 9m 23m 27m 27m 62m 73m
Returned to shareholders
Dividends — — — 4 0 — — — —
Total returned — — — 4 0 — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $194m
Short-term assets $192mLonger-term assets $2m
What it owes, and who funded it · $194m
Short-term liabilities $11mLonger-term liabilities $0mShareholders' equity $183m
  • Short-term assets cover short-term liabilities $192m of assets due within a year against $11m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $192m short-term assets against $0 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Whitehawk Therapeutics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+78.2%
year over year
R&D spending
1273.1%
of revenue
Sales & admin spending
417.4%
of revenue

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -100.0% 12.6% 167 of 172
Change in growth rate Growth +0.0pp -0.1pp 83 of 172
Gross margin Profitability 89.4% 82.4% 23 of 75
Operating margin Profitability -1601.1% -189.4% 143 of 175
Net margin Profitability -288.3% -157.3% 110 of 180
Free-cash-flow margin Cash generation -1371.4% -145.4% 146 of 176
Stock pay as % of revenue Cash generation 138.2% 19.2% 145 of 179
Change in share count Balance sheet 78.2% 7.9% 149 of 156

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$198M
Institutions reporting
78
Shares held vs prior quarter
▲ 22.9%
Positions opened / closed
29 / 11

Top buyers and sellers, Q2 2026: 58 institutions bought and 22 sold ; the biggest buyer was Yu Fan (+2.8M shares) and the biggest seller Stempoint Capital LP (−858K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Yu Fan $22.3M 4.9M 11.2% ▲ 134.8%
Acuta Capital Partners, LLC $21.5M 4.7M 10.8% ▲ 37.4%
Qvt Financial LP $21.1M 4.6M 10.7% 0.0%
Montanova Capital, LLC $19.7M 4.3M 9.9% ▲ 16.2%
Orbimed Advisors LLC $18M 3.9M 9.1% ▼ 5.6%
Avoro Capital Advisors LLC $13.1M 2.8M 6.6% 0.0%
Siren, L.L.C. $10.7M 2.3M 5.4% ▲ 12.3%
Kvp Capital Advisors, LP $9.9M 2.2M 5.0% 0.0%
Blackrock, Inc. $8.8M 1.9M 4.4% ▲ 447.2%
Vanguard Capital Management LLC $6.4M 1.4M 3.2% ▲ 5.5%
ADAR1 Capital Management, LLC $6.1M 1.3M 3.1% ▲ 943.9%
Acorn Capital Advisors, LLC $5.2M 1.1M 2.6% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Whitehawk Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $2.6M 14 trades by 3 insiders · 0% under pre-set plans
Net ▼ $2.6M net selling
Insider Date Trade Shares Price Value
Giacobello Scott M. CHIEF FINANCIAL OFFICER April 16, 2026 Sell 141,600 $4.13 $584,808
Giacobello Scott M. CHIEF FINANCIAL OFFICER April 15, 2026 Sell 77,000 $3.86 $297,220
Ball Bryan See remarks April 14, 2026 Sell 92,460 $3.64 $336,554
Ball Bryan See remarks April 13, 2026 Sell 26,389 $3.46 $91,306
Ball Bryan See remarks April 10, 2026 Sell 6,596 $3.43 $22,624
Lennon David James CHIEF EXECUTIVE OFFICER April 9, 2026 Sell 14,500 $3.38 $49,010
Ball Bryan See remarks April 9, 2026 Sell 50,000 $3.57 $178,500
Lennon David James CHIEF EXECUTIVE OFFICER April 8, 2026 Sell 63,945 $3.40 $217,413
Lennon David James CHIEF EXECUTIVE OFFICER April 7, 2026 Sell 94,087 $3.43 $322,718
Lennon David James CHIEF EXECUTIVE OFFICER April 6, 2026 Sell 102,395 $3.51 $359,406
Lennon David James CHIEF EXECUTIVE OFFICER April 2, 2026 Sell 26,858 $3.48 $93,466
Ball Bryan See remarks March 2, 2026 Sell 1,834 $3.31 $6,071

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 7, 2026
  • March 12, 2026
  • November 6, 2025
  • August 7, 2025
  • May 8, 2025

Recent SEC filings

Data status

When each part of this page on Whitehawk Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Whitehawk Therapeutics, Inc. in brief

What does Whitehawk Therapeutics, Inc. do?
Whitehawk Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Whitehawk Therapeutics, Inc.'s stock ticker?
Whitehawk Therapeutics, Inc. trades under the ticker WHWK on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Whitehawk Therapeutics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Whitehawk Therapeutics, Inc. reported revenue of $0, 100.0% lower than a year earlier, according to its SEC filings.
What is Whitehawk Therapeutics, Inc.'s free cash flow?
Whitehawk Therapeutics, Inc.'s free-cash-flow margin is -1371.4% of revenue over the trailing twelve months, ranking 146 of the 176 biotechnology companies we cover.
Who are Whitehawk Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Yu Fan, Acuta Capital Partners, LLC and Qvt Financial LP. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Whitehawk Therapeutics, Inc.'s market cap?
On November 2, 2026, Whitehawk Therapeutics, Inc.'s market capitalisation was about $227M and net debt of -$85.2M. Market figures come from third-party market data and may be delayed.
Are insiders buying or selling Whitehawk Therapeutics, Inc. stock?
Over the last 12 months, Whitehawk Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 14 sales on Form 4. The insider trading page charts every trade.
When is Whitehawk Therapeutics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Whitehawk Therapeutics, Inc. announces its own schedule.